<DOC>
	<DOCNO>NCT00725725</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness Org 25935 vs. placebo give combination cognitive-behavioral therapy ( CBT ) reduce symptom panic disorder . It hypothesize treatment Org 25935 dose 4 mg 12 mg differ significantly placebo respect Panic Disorder Severity Scale ( PDSS ) total score 3 week therapy .</brief_summary>
	<brief_title>Org 25935 Versus Placebo Augmentation Cognitive-behavioral Therapy Treat Panic Disorder ( P05705 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<criteria>male , female childbearing potential nonpregnant , nonlactating use medically accept method contraception . age 18 65 , inclusive ; sign write informed consent scope nature investigation explain Screening evaluation ; fluent English ; diagnose Screening current panic disorder , without agoraphobia ; Clinical Global Impressions ( CGI ) Severity score Screening &gt; = 4 &lt; = 6 ; currently take psychotropic medication able willing discontinue medication prior first CBT session . Antidepressant anxiolytic medication acceptable stabilize least 8 week prior Screening ; able complete schedule assessment treatment visit willing comply requirement study protocol . diagnose primary Axis I disorder panic disorder ; Screening MontgomeryAsberg Depression Rating Scale ( MADRS ) score &gt; = 35 ( severe depression ) ; history bipolar disorder , psychotic disorder , obsessive compulsive disorder ; diagnosis post traumatic stress disorder , eat disorder , substance abuse dependence ( exclude nicotine ) within past six month ; know suspect significant personality dysfunction could , investigator 's opinion , interfere trial participation . Participants know borderline avoidant personality disorder exclude ; imminent risk selfharm harm others , investigator 's opinion base clinical interview response provide Columbia Suicide Severity Rating Scale ( CSSRS ) . Participants must exclude report suicidal ideation Type 4 5 past 3 month suicidal behavior past 12 month measure CSSRS Screening ; currently psychiatric inpatient hospitalize psychiatric condition within past year ; ever diagnose organic brain syndrome , mental retardation , cognitive dysfunction could interfere capacity participate CBT complete safety efficacy assessment ; history head trauma cause ongoing cognitive impairment ; history seizure ( apart childhood febrile seizure ) ; uncontrolled , unstable clinically significant medical condition ( e.g. , renal , endocrine , hepatic , respiratory , cardiovascular , hematologic , immunologic cerebrovascular disease , malignancy ) may interfere interpretation safety efficacy evaluation opinion investigator ; clinically relevant visual disturbance , cataract , color blindness , macular degeneration , glaucoma , retinal disease ; clinically significant abnormal laboratory , vital sign , physical examination , electrocardiogram ( ECG ) finding Screening may interfere interpretation safety efficacy assessment opinion investigator ; Corrected QT interval ( QTc ) value &gt; 450 millisecond Screening use Bazett 's QTc formula ; female , positive result serum pregnancy test ( Screening ) , plan become pregnant course trial ; positive urine drug alcohol breath test Screening , unless positive finding account documented prescription use ; unable unwilling comply investigator 's instruction regard drug alcohol use trial period ; history sensitivity/idiosyncrasy glutamatergic drug chemically related compound excipients may employ trial unknown drug use past ; receive concurrent psychotherapy treatment panic disorder [ general supportive psychotherapy acceptable therapy initiate least 3 month prior Screening ] receive prior adequate trial CBT panic disorder ; expose investigational drug within 6 month prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>